HC Wainwright Forecasts Strong Price Appreciation for Monopar Therapeutics (NASDAQ:MNPR) Stock

Monopar Therapeutics (NASDAQ:MNPR) had its price objective lifted by research analysts at HC Wainwright from $6.00 to $22.00 in a research report issued on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price objective indicates a potential upside of 27.54% from the company’s current price.

Separately, Rodman & Renshaw initiated coverage on Monopar Therapeutics in a research note on Friday, October 11th. They set a “buy” rating and a $50.00 price target on the stock.

Monopar Therapeutics Stock Up 3.5 %

MNPR opened at $17.25 on Monday. Monopar Therapeutics has a 52 week low of $1.37 and a 52 week high of $38.50. The business has a 50 day moving average price of $7.84 and a two-hundred day moving average price of $4.91. The company has a market cap of $68.31 million, a PE ratio of -8.46 and a beta of 1.09.

Monopar Therapeutics (NASDAQ:MNPR) last issued its quarterly earnings results on Friday, November 8th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.09. As a group, sell-side analysts expect that Monopar Therapeutics will post -1.93 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CFO Karthik Radhakrishnan acquired 1,550 shares of the business’s stock in a transaction on Monday, October 28th. The shares were bought at an average cost of $16.25 per share, with a total value of $25,187.50. Following the completion of the transaction, the chief financial officer now directly owns 1,550 shares of the company’s stock, valued at $25,187.50. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 34.90% of the company’s stock.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.